Stockscreener 앱 받기
0.1271
0.89%
-0.0642
전일 마감가:
$0.1913
열려 있는:
$0.130175
하루 거래량:
7,034
Relative Volume:
66.00
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.89%
1개월 성능:
-50.08%
6개월 성능:
-75.69%
1년 성능:
-92.59%
1일 변동 폭
$0.127
$0.1334
1주일 범위
$0.127
$0.1334
52주 변동 폭
$0.127
$0.1334
Nkgen Biotech Inc Stock (NKGN) Company Profile
NKGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.1271 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Nkgen Biotech Inc 주식(NKGN)의 최신 뉴스
NKGen Biotech secures amended loan terms with East West Bank By Investing.com - Investing.com India
NKGen Biotech secures amended loan terms with East West Bank - Investing.com
NKGen Biotech (NYSE:NKGN) Trading Up 4.3% – Here’s What Happened - Defense World
NKGen Biotech To Present on the Use of Troculeucel for - GlobeNewswire
Breakthrough NK Cell Therapy Data Reveals New Hope for Alzheimer's Patients - Stock Titan
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial - GlobeNewswire
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) - Yahoo
NKGen Biotech Delays Annual Report Filing - TipRanks
NKGen Biotech to Present Phase 1 Results on Troculeucel NK Cell Therapy for Alzheimer's at AD/PD™ 2025 Conference - Nasdaq
NKGen Biotech To Present Updated Troculeucel Data at the - GlobeNewswire
Groundbreaking NK Cell Therapy Data for Alzheimer's: 6-Month Results to be Revealed at Major Conference - Stock Titan
NKGen Biotech To Present on Potential of Troculeucel for - GlobeNewswire
NKGen Biotech to Present Troculeucel as Potential Neurodegenerative Disease Therapy at Alzheimer’s & Parkinson’s Drug Development Summit - Nasdaq
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit - GlobeNewswire
Revolutionary NK Cell Therapy Advances Against Alzheimer's: FDA Fast-Tracks Promising Treatment - StockTitan
NKGen Biotech secures $5 million convertible loan By Investing.com - Investing.com South Africa
NKGen Biotech secures $5 million convertible loan - Investing.com India
4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal
NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split - TipRanks
NKGen Biotech shifts to OTC Markets after Nasdaq delisting By Investing.com - Investing.com South Africa
NKGen Biotech shifts to OTC Markets after Nasdaq delisting - Investing.com India
NKGen Biotech, Inc. to Transition from the Nasdaq Global - GlobeNewswire
NKGen Biotech Delisted: What Happens to Its FDA Fast-Tracked Alzheimer's Program Now? - StockTitan
NKGen Biotech, Inc. SEC 10-Q Report - TradingView
Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program - The Manila Times
NKGen Biotech announces administration of first dose of troculeucel - TipRanks
Can NK Cell Therapy Help Stroke Patients? NKGen's FDA-Cleared Treatment Begins Testing - StockTitan
NKGen Biotech Doses First FTD Patient With Troculeucel Under FDA Compassionate Use - Nasdaq
NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
NKGen Biotech Announces Administration of First Dose of - GlobeNewswire
Groundbreaking Brain Barrier-Crossing Treatment Starts in Frontotemporal Dementia PatientWill NK Cells Change Neurology? - StockTitan
NKGen Biotech Inc (NKGN) At $0.48: It’s Worth Your Interest - Stocks Register
NKGen Appoints Dr. Anita Fletcher as National Principal - GlobeNewswire
NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer'S Disease With Adventhealth Orlando As First East Coast Site - Marketscreener.com
Can This NK Cell Therapy Transform Alzheimer's Treatment? Phase 1 Shows Remarkable 90% Success - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Midday Stock Roundup: RxSight Down 6.1% on Weak Post-3Q Results - Orange County Business Journal
FDA fast tracks NKGen's Alzheimer's therapy troculeucel - MSN
NKGen Biotech Announces Publication of Phase 1 Troculeucel - GlobeNewswire
Market cap of NKGen Biotech Inc [NKGN] reaches 37.83M – now what? - The DBT News
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
NKGen's Troculeucel Therapy Demonstrates Stability And Cognitive Improvement In AD Trial - Nasdaq
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the ... - The Bakersfield Californian
Revolutionary Alzheimer's Treatment Shows Remarkable 90% Success in Phase 1 Trial - StockTitan
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket - Benzinga India
FDA Fast Track Designation Sends Biotech Soaring Mid-Week - The Globe and Mail
FDA fast tracks NKGen's Alzheimer's therapy troculeucel By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Nkgen Biotech Inc (NKGN) 재무 분석
Nkgen Biotech Inc (NKGN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):